Compare BioNano Genomics Inc (BNGO) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Dollar Tree, Inc. — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Dollar Tree, Inc. trades at $128.55 (market cap $24.61B). The key difference: Dollar Tree, Inc. is far larger — about 1801.6× BioNano Genomics Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | DLTR | |
|---|---|---|
Market Cap | $13.66M | $24.61B |
Sector | Health | Health |
52-Week High | $4.92 | $141.21 |
52-Week Low | $1.06 | $85.04 |
Enterprise Value | $16.26M | $31.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Dollar Tree (DLTR) trades at $128.76, down 0.47% on the day. The stock exhibits a bullish technical trend, trading near its pivot point of $128 with support at $127. Fundamentally, the company reported a net loss of -$3.03B for 2025 despite strong operating cash flow of $2.86B. Recent news highlights a $2.5 billion share repurchase authorization announced on July 2, 2026 (Business Wire).
The outlook is mixed. Analyst consensus is a 'Buy' with a $126.69 price target, but significant risks exist from recent profitability challenges and competitive pressures. The share repurchase program may support EPS, but investors should weigh the negative net income against improving operational cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
